Why Ionis Pharmaceuticals' (IONS) 2026 Catalyst Pipeline Supported Leerink's Higher Target [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best growth stocks to buy according to billionaires As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street. Based on 21 analyst targets, the average price target stood at $89.00, with a high target of $110.00 and a low target of $39.00. Using the share price in that March 13 snapshot, the average target implied roughly 25% upside. Why Ionis Pharmaceuticals' 2026 Catalyst Pipeline Supported Leerink's Higher Target Likoper/Shutterstock.com The bullish stance came as Ionis entered 2026 with a fuller commercial and pipeline story than a simple rating change might suggest. On February 25, 2026, the company reported full-year 2025 revenue of $944 million, up 34% from 2024, helped by the commercial launch of TRYNGOLZA and a $280 million upfront payment from Ono Pharmaceutical. Ionis also said it expects 2026 revenue of $800 million to $825 million on a like-for-like basis
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- National Triglyceride Alliance Celebrates One Year of Impact and Recognizes National Triglycerides Day [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Ionis announces changes to Board of DirectorsBusiness Wire
- Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an "outperform" rating on the stock.MarketBeat
- Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 3/18/26 - Form 4
- 3/16/26 - Form 144
- 3/11/26 - Form 4
- IONS's page on the SEC website